-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Upgrades Cartesian Therapeutics to Overweight, Announces $16 Price Target

Benzinga·03/09/2026 16:54:09
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutral to Overweight and announces $16 price target.